WHAT IS CLAIMED IS:

1	1. An isolated UCP2 polypeptide, said UCP2 polypeptide comprising at
2	least 164 consecutive amino acid residues of the amino acid sequence set forth in SEQ. ID.
3	NO: 1, said consecutive amino acid residues comprising an alanine at amino acid residue 55
4	and a threonine at amino acid residue 219 of SEQ. ID. NO: 1.
1	2. The isolated UCP2 polypeptide in accordance with claim 1, wherein
2	said UCP2 polypeptide has the amino acid sequence set forth in SEQ. ID. NO: 1.
1	3. The isolated UCP2 polypeptide in accordance with claim 1, wherein
2	said UCP2 polypeptide is encoded by the nucleic acid sequence set forth in SEQ. ID. NO: 2.
1	4. An isolated nucleic acid that encodes a UCP2 polypeptide, wherein the
2	codon for amino acid residue 55 (Ala) is a member selected from the group consisting of
	` , ,
3	GCT, GCC, GCA and GCG, and the codon for amino acid residue 219 (Thr) is a member
4	selected from the group consisting of ACT, ACC, ACA and ACG.
1	5. The isolated nucleic acid that encodes a UCP2 polypeptide in
2	accordance with claim 4, wherein said codon for amino acid residue 55 is GCC.
1	6. The isolated nucleic acid that encodes a UCP2 polypeptide in
2	accordance with claim 4, wherein said codon for amino acid residue 219 is ACT.
1	7. The isolated nucleic acid that encodes a UCP2 polypeptide in
1	
2	accordance with claim 4, wherein said UCP2 polypeptide has the amino acid sequence set
3	forth in SEQ. ID. NO: 1.
1	8. The isolated nucleic acid that encodes a UCP2 polypeptide in
2	accordance with claim 4, wherein said nucleic acid has the nucleic acid sequence set forth in
3	SEQ. ID. NO: 2.

	1	9. An isolated nucleic acid that encodes the UCP2 polypeptide of claim 1,
	2	wherein a codon for amino acid residue 55 (Ala) is a member selected from the group
	3	consisting of GCT, GCC, GCA and GCG, and a codon for amino acid residue 219 (Thr) is a
	4	member selected from the group consisting of ACT, ACC, ACA and ACG.
	1	10. An isolated nucleic acid that encodes a UCP2 polypeptide in accordance
	2	with claim 4, wherein said nucleic acid is operably linked to a promoter.
	1	11. An isolated nucleic acid that encodes a UCP2 polypeptide in accordance
J Million	2	with claim 10, wherein said nucleic acid is contained in an expression vector.
T.	1	12. An expression vector containing the nucleic acid of claim 4 in operative
III P	2	association with a regulatory element that controls expression of the nucleic acid in a host
	3	cell.
91	1	13. A cell comprising a recombinant nucleic acid in accordance with claim
	2	4.
	1	14. A cell in accordance with claim 13, wherein said recombinant nucleic
	2	acid is in operative association with a regulatory element that controls the expression of the
• •	3	nucleic acid in a host cell.
	1	15. A method of making a UCP2 polypeptide, said method comprising:
	2	introducing a nucleic acid of claim 4 into a host cell or cellular extract;
	3	incubating said host cell or cellular extract under conditions such that
	4	said UCP2 polypeptide is expressed in said host cell or cellular extract; and
	5	recovering said UCP2 polypeptide from said host cell or cellular extract.
	1	16. A method for diagnosing body weight disorders, said method
	2	comprising detecting in a patient sample, the level of:

	3	a. an mRNA transcribed from a nucleic acid encoding a UCP2
	4	polypeptide having the amino acid sequence set forth in SEQ. ID.
	5	NO: 1;
	6	b. a UCP2 polypeptide having the amino acid sequence set forth in
	7	SEQ. ID. NO: 1; or
	8	c. a UCP2 polypeptide encoded by the nucleic acid sequence set forth
	9	in SEQ. ID. NO: 2.
	1	17. The method in accordance with claim 16, wherein the level is induced
	2	in overweight individuals.
	1	18. The method in accordance with claim 16, wherein the level is repressed
	2	in overweight individuals.
	1	19. The method in accordance with claim 16, wherein the level is induced
	2	in underweight individuals.
	1	20. The method in accordance with claim 16, wherein the level is repressed
	2	in underweight individuals.
	1	21. A method of treating obesity in a mammal, said method comprising
	2	administering to said mammal a therapeutically effective amount of a UCP2 polypeptide and
	3	a pharmaceutically acceptable carrier.
	1	22. A method of identifying a modulator of UCP2 gene expression, said
	2	method comprising:
	3	providing a cell comprising a UCP2 promoter operably linked to a
	4	reporter gene;
	5	contacting said cell with a test compound that is a potential modulator
	6	of UCP2 gene expression; and
	7	detecting the expression level of the reporter gene, wherein an increase
	8	or decrease in reporter gene expression in the presence of the test compound compared to

- 9 reporter gene expression in the absence of the test compound indicates that the test
- 10 compound is a modulator of UCP2 gene expression.
- 1 23. The method according to claim 22, wherein the test compound causes
- 2 an increase in reporter gene expression.